![list of clinical trials done on xarelto rivaroxaban list of clinical trials done on xarelto rivaroxaban](https://www.drugdiscoverytrends.com/wp-content/uploads/2019/09/Xarelto.jpg)
Full dose apixaban (5 mg ) can be used, unless at least two of the following characteristics apply: patient age is 80 years or older, body weight is 60 kg or less, and serum creatinine is 1.5 mg/dL or higher, in which case dose reduction to 2.5 mg bid is indicated. While apixaban may be used in people with severely decreased kidney function and those on hemodialysis it has not been studied in these groups. Īpixaban and other anticoagulants ( dabigatran, edoxaban and rivaroxaban) appear equally effective as warfarin in preventing non-hemorrhagic stroke in people with atrial fibrillation and are associated with lower risk of intracranial bleeding. Atrial fibrillation Īpixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes mellitus, or symptomatic heart failure. In the EU, apixaban is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, and for the prevention of recurrent DVT and PE in adults. To reduce the risk of recurring DVT and PE after initial therapy.DVTs may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. Deep vein thrombosis (DVT) prevention.To lower the risk of stroke and embolism in people with nonvalvular atrial fibrillation.Īpixaban is indicated for the following:
![list of clinical trials done on xarelto rivaroxaban list of clinical trials done on xarelto rivaroxaban](https://www.xareltohcp.com/sites/www.xareltohcp-v1.com/files/faq_proceduralcharacteristics_d.png)
Though generics of apixaban were approved by the FDA since 2017, due to patent infringement lawsuits, generics of will most likely not be available for sale commercially until at least 2026. In 2019, it was the 52nd most commonly prescribed medication in the United States with more than 14 million prescriptions. It is on the World Health Organization's List of Essential Medicines. Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012. In 2007, Pfizer and Bristol-Myers Squibb began development of apixaban as an anticoagulant. Compared to warfarin it has fewer interactions with other medications. Use appears to be relatively safe in those with mild kidney problems.
![list of clinical trials done on xarelto rivaroxaban list of clinical trials done on xarelto rivaroxaban](https://hips.hearstapps.com/hmg-prod.s3.amazonaws.com/images/gettyimages-rivaroxaban-1543409778.jpg)
Use is not recommended during pregnancy or breastfeeding. Other side effects may include bleeding around the spine and allergic reactions. Ĭommon side effects include bleeding and nausea. It is used as an alternative to warfarin and does not require monitoring by blood tests or dietary restrictions. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.